Nulojix launched for immunosuppression in renal transplantation

Nulojix (belatacept) is indicated for use in combination with corticosteroids and mycophenolate to prevent graft rejection in renal transplantation.

New intravenous therapy for immunosuppression
New intravenous therapy for immunosuppression


Belatacept is a soluble fusion protein consisting of a modified segment of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) fused to a portion of a human immunoglobulin G1. By selectively blocking T cell co-stimulation, belatacept helps protect renal allografts from immunological rejection.


Two studies evaluated the safety and efficacy of belatacept as part of an immunosuppressive  regimen following renal transplantation. Two dosage regimens (one more and one less intensive) were compared with ciclosporin, with all patients receiving basiliximab, mycophenolate and corticosteroids. Efficacy was the same for both regimens but the overall safety and tolerability was better for the lower intensity regimen; consequently, it is the lower dosage regimen that is licensed.

Patient and graft survival were similar for the lower intensity regimen and ciclosporin in both studies but fewer patients treated with belatacept met the composite renal impairment endpoint. Additionally, the mean GFR was higher in patients treated with belatacept than in those who received ciclosporin.

View Nulojix drug record

Further information: Bristol-Myers Squibb Pharmaceuticals Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases